natgillin/translations-raw huggingface dataset:
However, patients who developed venous thrombosis while receiving therapy did not appear to have an increased rate of Grade 3 or above bleeding when treated with a full dose of warfarin and bevacizumab concomitantly (NCI-CTCAE v.3). 
Vendar pa pri bolnikih, pri katerih se je med zdravljenjem pojavila venska tromboza, niso ugotovili povečane pogostnosti krvavitev 3. ali višje stopnje (NCI-CTCAE v.3), kadar so jih sočasno zdravili s polnim odmerkom varfarina in bevacizumabom.
Parenteral medicinal products should be inspected visually for particulate matter and discolouration prior to administration. 
Zdravila za parenteralno dajanje je treba pred uporabo vizualno pregledati glede prisotnosti trdnih delcev in obarvanosti.
Ninety seven (97) patients in the IFN alfa-2a arm and 131 patients in the bevacizumab arm reduced the dose of IFN alfa-2a from 9 MIU to either 6 or 3 MIU three times a week as pre-specified in the protocol. 
Sedemindevetdesetim (97) bolnikom iz skupine, ki je prejemala IFN alfa-2a, in 131 bolnikom iz skupine, ki je prejemala bevacizumab, so v skladu s protokolom zmanjšali odmerek IFN alfa-2a z 9 mio i.e. na 6 ali 3 mio i.e. trikrat na teden.
s r.o. 
kot i.v.
The frequency of GI-vaginal fistulae in the group treated with bevacizumab + chemotherapy was higher in patients with recurrence within the field of prior radiation (16.7%) compared with patients with no prior radiation and/ or no recurrence inside the field of prior radiation (3.6%). 
Pogostnost fistul med prebavili in nožnico v skupini, ki se je zdravila z bevacizumabom in kemoterapijo, je bila večja pri bolnicah s ponovitvijo bolezni v območju predhodnega obsevanja (16,7 %) v primerjavi z bolnicami brez predhodnega obsevanja in/ali brez ponovitve v območju predhodnega obsevanja (3,6 %).
Zirabev is administered in combination with one of the following chemotherapy regimens: paclitaxel and cisplatin or paclitaxel and topotecan. 
Zdravilo Zirabev dajemo v kombinaciji z 1 od naslednjih shem kemoterapije: paklitaksel in cisplatin ali paklitaksel in topotekan.
Median OS (months) HR (95% CI) p-value 
mediano OS (meseci) HR (95 % IZ) p-vrednost
The primary endpoint was progression free survival, secondary endpoints for the trial included the duration of overall survival. 
Primarni opazovani dogodek je bilo preživetje brez napredovanja bolezni, sekundarni opazovani dogodki v preskušanju pa so vključevali tudi trajanje celokupnega preživetja.
Palmar-plantar erythrodysaesthesia syndrome 
, sindrom palmarno-plantarne eritrodisestezije
Clinical safety data suggest that the incidence of minor mucocutaneous haemorrhage (e.g. epistaxis) may be dose-dependent. 
Klinični podatki o varnosti kažejo, da je pojavnost manjših kožnih in sluzničnih krvavitev (na primer epistaksa) lahko odvisna od odmerka.
PHARMACEUTICAL FORM Concentrate for solution for infusion (sterile concentrate). 
koncentrat za raztopino za infundiranje (sterilni koncentrat)
Four patients had objective (partial) response, and all of these had received the 10 mg/kg dose bevacizumab; the ORR for the 10 mg/kg dose was 10%. 
Štirje bolniki so dosegli objektivni (delni) odziv; vsi so prejemali bevacizumab v odmerku 10 mg/kg.
There is no information on the effect of bevacizumab in patients with uncontrolled hypertension at the time of initiating therapy. 
O učinku bevacizumaba pri bolnikih z nenadzorovano hipertenzijo ob začetku zdravljenja ni podatkov.
For dilution and other handling recommendations, see section 6.6. 
Za redčenje in ostala priporočila glede ravnanja z zdravilom glejte poglavje 6.6.
The safety and efficacy of the recommended dose (5 mg/kg of body weight every two weeks) in metastatic carcinoma of the colon or rectum were studied in three randomised, active-controlled clinical trials in combination with fluoropyrimidine-based first-line chemotherapy. 
Varnost in učinkovitost priporočenega odmerka (5 mg/kg telesne mase vsaka 2 tedna) pri bolnikih z metastatskim karcinomom debelega črevesa in danke so proučevali v 3 randomiziranih, z učinkovino nadzorovanih kliničnih preskušanjih v kombinaciji s kemoterapijo na osnovi fluoropirimidina v prvi liniji zdravljenja.
In addition, hypertension (including hypertensive crisis), elevated creatinine, and neurological symptoms were observed in some of these patients. 
Pri nekaterih od teh bolnikov so opazili tudi hipertenzijo (vključno s hipertenzivno krizo), zvečane vrednosti kreatinina in nevrološke simptome.
No increase in the incidence of other reactions, including gastrointestinal perforation, wound healing complications, congestive heart failure, and haemorrhage was observed in elderly patients (> 65 years) receiving bevacizumab as compared to those aged ≤ 65 years treated with bevacizumab. 
Povečane pojavnosti drugih neželenih učinkov, vključno s perforacijo prebavil, zapleti pri celjenju ran, kongestivnim srčnim popuščanjem in krvavitvijo, pri starejših bolnikih (> 65 let), ki so prejemali bevacizumab, v primerjavi z bolniki, starimi ≤ 65 let, ki so se zdravili z bevacizumabom, niso opazili.
In these studies, bevacizumab was administered at the following dosing regimens in combination with FOLFOX-4 (5-FU/LV/oxaliplatin), XELOX (capecitabine/oxaliplatin), and fluoropyrimidine/irinotecan and fluoropyrimidine/oxaliplatin: 
V teh študijah so bevacizumab dajali v kombinaciji s shemo FOLFOX-4 (5-FU/LV/oksaliplatin), shemo XELOX (kapecitabin/oksaliplatin) ter shemo fluoropirimidin/irinotekan in fluoropirimidin/oksaliplatin po naslednjih režimih odmerjanja:
In patients developing PRES, early recognition of symptoms with prompt treatment of specific symptoms including control of hypertension (if associated with severe uncontrolled hypertension) is recommended in addition to discontinuation of bevacizumab therapy. 
Pri bolnikih, pri katerih se razvije PRES, je poleg prekinitve zdravljenja z bevacizumabom priporočljivo zgodnje odkrivanje simptomov s hitrim zdravljenjem specifičnih simptomov, vključno z obvladovanjem hipertenzije (če je motnja povezana s hudo nenadzorovano hipertenzijo).
In this trial arterial thromboembolic reactions were observed in 11% (11/100) of patients compared to 5.8% (6/104) in the chemotherapy control group. 
V tem preskušanju so arterijske trombembolične dogodke opazili pri 11 % bolnikov (11/100) v primerjavi s kontrolno skupino, ki je prejemala samo kemoterapijo, kjer so te dogodke opazili pri 5,8 % bolnikov (6/104).
Patients treated for persistent, recurrent, or metastatic cervical cancer with bevacizumab in combination with paclitaxel and cisplatin may be at increased risk of venous thromboembolic events. 
Pri bolnicah z dolgotrajnim, ponavljajočim se ali metastatskim rakom materničnega vratu, ki se zdravijo z bevacizumabom v kombinaciji s paklitakselom in cisplatinom, lahko obstaja povečano tveganje za venske trombembolične dogodke.
Close observation of the patient during and following the administration of bevacizumab is recommended as expected for any infusion of a therapeutic humanised monoclonal antibody. 
Priporočljivo je, da bolnika med dajanjem bevacizumaba in po njem skrbno spremljamo, kot je to običajno pri vsakem infundiranju terapevtskega humaniziranega monoklonskega protitelesa.
After completion of six cycles of carboplatin-paclitaxel chemotherapy or upon premature discontinuation of chemotherapy, patients on the bevacizumab + carboplatin-paclitaxel arm continued to receive bevacizumab as a single agent every 3 weeks until disease progression. 
Po zaključku 6 ciklov kemoterapije s karboplatinom in paklitakselom ali po predčasni prekinitvi kemoterapije so bolniki v skupini, ki je prejemala bevacizumab + karboplatin in paklitaksel, do napredovanja bolezni prejemali samo bevacizumab vsake 3 tedne.
• Pregnancy (see section 4.6). 
Nosečnost (glejte poglavje 4.6).
Zirabev therapy should be discontinued in patients who develop necrotising fasciitis, and appropriate treatment should be promptly initiated. 
Pri bolnikih, pri katerih se razvije nekrotizirajoči fasciitis, je treba zdravljenje z zdravilom Zirabev prekiniti in takoj uvesti ustrezno zdravljenje.
In clinical trials with bevacizumab, congestive heart failure (CHF) was observed in all cancer indications studied to date, but occurred predominantly in patients with metastatic breast cancer. 
V kliničnih preskušanjih z bevacizumabom so kongestivno srčno popuščanje (KSP) opazili pri vseh indikacijah raka, ki so jih preučevali do sedaj, pojavilo pa se je predvsem pri bolnikih z metastatskim rakom dojk.
Efficacy results for trials AVF0780g and AVF2192g AVF0780g 
Preglednica 5 Rezultati učinkovitosti v preskušanjih AVF0780g in AVF2192g
In an exploratory retrospective analysis of data from 13 completed randomised trials in patients with various tumour types, 3 patients out of 91 (3.3%) with brain metastases experienced CNS bleeding (all Grade 4) when treated with bevacizumab, compared to 1 case (Grade 5) out of 96 patients (1%) that were not exposed to bevacizumab. 
V raziskovalni retrospektivni analizi podatkov iz 13 zaključenih randomiziranih preskušanj pri bolnikih z različnimi vrstami tumorjev se je krvavitev v CŽS (pri vseh stopnje 4) pojavila pri 3 bolnikih od skupno 91 (3,3 %) bolnikov, ki so imeli metastaze v možganih in so se zdravili z bevacizumabom, v primerjavi z 1 primerom (stopnja 5) pri skupno 96 bolnikih (1 %), ki jih niso izpostavili bevacizumabu.
• AVF0780g: In combination with bolus 5-fluorouracil/folinic acid (5-FU/FA) for a total of 6 weeks of each 8 week-cycle (Roswell Park regimen). 
AVF0780g: v kombinaciji z bolusom 5-fluorouracila in folinsko kislino (5-FU/FAfolinic acid), skupaj 6 tednov v vsakem 8-tedenskem ciklu (shema Roswell Park).
The VEGF protein causes blood vessels to grow within tumours, these blood vessels provide the tumour with nutrients and oxygen. 
Beljakovina VEGF v tumorjih omogoča rast krvnih žil, ki tumor oskrbujejo s hranili in kisikom.
No clinically relevant interaction of bevacizumab was observed on the pharmacokinetics of co-administered interferon alpha 2a, erlotinib (and its active metabolite OSI-420), or the chemotherapies irinotecan (and its active metabolite SN38), capecitabine, oxaliplatin (as determined by measurement of free and total platinum), and cisplatin. 
Klinično pomembnega delovanja bevacizumaba na farmakokinetiko sočasno danega interferona alfa-2a, erlotiniba (in njegovega aktivnega presnovka OSI-420) ali kemoterapevtikov irinotekana (in njegovega aktivnega presnovka SN38), kapecitabina, oksaliplatina (določeno z merjenjem proste in celokupne platine) in cisplatina niso opazili.
b 10 mg/kg every 2 weeks. 
10 mg/kg vsaka 2 tedna.
Table 4 Efficacy results for trial AVF2107g 
Preglednica 4 Rezultati učinkovitosti v preskušanju AVF2107g
Once bevacizumab is bound to VEGF, tumour growth is prevented by blocking the growth of the blood vessels which provide the nutrients and oxygen to the tumour. 
Bevacizumab z vezavo na VEGF prepreči rast tumorja tako, da zavira rast krvnih žil, ki tumor oskrbujejo s hranili in kisikom.
Grade 3 hypertension was 60.0% in patients treated with bevacizumab in combination with erlotinib compared to 11.7% in patients treated with erlotinib alone. 
Hipertenzija stopnje 3 je bila prisotna pri 60,0 % bolnikov, ki so se zdravili z bevacizumabom v kombinaciji z erlotinibom, v primerjavi z 11,7 % bolnikov, ki so se zdravili samo z erlotinibom.
It is recommended that treatment be continued until progression of the underlying disease or until unacceptable toxicity. 
Zdravljenje je priporočljivo nadaljevati do napredovanja osnovne bolezni ali nesprejemljive toksičnosti.
Serious wound healing complications, including anastomotic complications, have been reported, some of which had a fatal outcome. 
Poročali so o resnih zapletih pri celjenju ran, vključno z zapleti pri anastomozah; nekateri od teh primerov so bili smrtni.
● A rare neurological side effect named posterior reversible encephalopathy syndrome (PRES) has been associated with bevacizumab treatment. 
● Zdravljenje z bevacizumabom je povezano z redkim nevrološkim neželenim učinkom, ki ga imenujemo sindrom posteriorne reverzibilne encefalopatije (PRES - posterior reversible encephalopathy syndrome).
In clinical trials, the incidence of arterial thromboembolic reactions including cerebrovascular accidents (CVAs), transient ischaemic attacks (TIAs) and myocardial infarctions (MIs) was higher in patients receiving bevacizumab in combination with chemotherapy compared to those who received chemotherapy alone. 
V kliničnih preskušanjih je bila pojavnost arterijskih trombemboličnih dogodkov, vključno s cerebrovaskularnimi insulti (CVI), prehodnimi možganskimi ishemijami (TIA - transient ischemic attack) in miokardnimi infarkti (MI), večja pri bolnikih, ki so prejemali bevacizumab v kombinaciji s kemoterapijo, v primerjavi s tistimi, ki so prejemali samo kemoterapijo.
Dose-reduction of IFN alfa-2a did not appear to affect the efficacy of the combination of bevacizumab and IFN alfa-2a based on PFS event free rates over time, as shown by a sub-group analysis. 
Analiza podskupine je pokazala, da zmanjšanje odmerka IFN alfa-2a ni vplivalo na učinkovitost kombinacije bevacizumaba in IFN alfa-2a glede na stopnje PFS brez dogodkov v tem času.
Grade 4 proteinuria (nephrotic syndrome) was seen in up to 1.4% of treated patients. 
Proteinurijo stopnje 4 (nefrotski sindrom) so opazili pri največ 1,4 % zdravljenih bolnikov.
Zirabev infusions should not be administered or mixed with glucose solutions. 
Infuzij zdravila Zirabev ne smemo dajati ali mešati skupaj z raztopinami glukoze.
• In a retrospective single institution series, 12 consecutive (2005 to 2008) children with relapsed or progressive high-grade glioma (3 with WHO Grade IV, 9 with Grade III) were treated with bevacizumab (10 mg/kg) and irinotecan (125 mg/m²) every 2 weeks. 
• V retrospektivni seriji primerov v 1 ustanovi so 12 zaporednih primerov otrok (med letoma 2005 in 2008) s ponavljajočim se ali napredovalim gliomom visoke stopnje (3 otroci s stopnjo IV po SZO, 9 otrok s stopnjo III po SZO) zdravili z bevacizumabom (10 mg/kg) in irinotekanom (125 mg/m2) vsaka 2 tedna.
Progression-free survival and objective response rate were inferior in the bevacizumab monotherapy arm compared to the FOLFOX-4 arm. 
Preživetje brez napredovanja bolezni in objektivni odziv na zdravljenje sta bila v skupini, ki se je zdravila z bevacizumabom v monoterapiji, inferiorna v primerjavi s skupino, ki se je zdravila po shemi FOLFOX-4.
Across all clinical trials, mucocutaneous haemorrhage has been seen in up to 50% of bevacizumabtreated patients. 
V vseh kliničnih preskušanjih so kožne in sluznične krvavitve opazili pri največ 50 % bolnikov, ki so se zdravili z bevacizumabom.
Very common (may affect more than 1 in 10 people) side effects, which were not severe, include: 
Zelo pogosti (pojavijo se lahko pri več kot 1 od 10 bolnikov) neželeni učinki, ki niso bili hudi, vključujejo:
Secondary efficacy endpoints included progression-free survival and objective response rate. 
Med sekundarnimi opazovanimi dogodki učinkovitosti sta bila preživetje brez napredovanja bolezni in objektivni odziv na zdravljenje.
6.6 Special precautions for disposal and other handling Zirabev should be prepared by a healthcare professional using aseptic technique to ensure the sterility of the prepared solution. 
Zdravilo Zirabev mora pripraviti zdravstveni delavec z aseptično tehniko, da zagotovi sterilnost pripravljene raztopine.
In study BO25041 of bevacizumab added to postoperative radiation therapy (RT) with concomitant and adjuvant temozolomide in paediatric patients with newly diagnosed supratentorial, infratentorial, cerebellar, or peduncular high-grade glioma, the safety profile was comparable with that observed in other tumour types in adults treated with bevacizumab. 
V študiji BO25041 z bevacizumabom, ki so ga dodali pooperativnemu obsevalnemu zdravljenju s sočasnim in adjuvantnim zdravljenjem s temozolomidom pri pediatričnih bolnikih z novo diagnosticiranim supratentorialnim, infratentorialnim, cerebelarnim ali pedunkularnim gliomom visoke stopnje, je bil varnostni profil primerljiv z varnostnim profilom pri drugih vrstah tumorjev pri odraslih, ki so se zdravili z bevacizumabom.
Severe reactions are defined as adverse reactions with at least a 2% difference compared to the control arm in clinical studies for NCI-CTCAE Grade 3-5 reactions. 
Hudi neželeni učinki so opredeljeni kot neželeni učinki z vsaj 2 % razliko v primerjavi s kontrolno skupino v kliničnih študijah za neželene učinke stopnje 3-5 po NCI-CTCAE.
• In a single-arm study (PBTC-022), 18 children with recurrent or progressive non-pontine high-grade glioma (including 8 with glioblastoma [WHO Grade IV], 9 with anaplastic astrocytoma [Grade III] and 1 with anaplastic oligodendroglioma [Grade III]) were treated with bevacizumab (10 mg/kg) two weeks apart and then with bevacizumab in combination with CPT-11 (125-350 mg/m²) once every two weeks until progression. 
• V študiji z 1 skupino (PBTC-022) se je 18 otrok s ponavljajočim se ali napredovalim gliomom visoke stopnje, ki se ni nahajal v ponsu (vključno z 8 otroki, ki so imeli glioblastom [stopnje IV po SZO], 9 otroki, ki so imeli anaplastični astrocitom [stopnje III], in 1 otrokom, ki je imel anaplastični oligodendrogliom [stopnje III]), zdravilo z bevacizumabom (10 mg/kg) v razmiku 2 tednov in nato z bevacizumabom v kombinaciji s CPT-11 (125-350 mg/m2) vsaka 2 tedna do napredovanja bolezni.
Most patients who developed CHF during mBC trials showed improved symptoms and/or left ventricular function following appropriate medical therapy. 
Pri večini bolnikov, pri katerih se je v preskušanjih pri mBC pojavilo KSP, so se simptomi in/ali iztisni delež levega prekata izboljšali po ustreznem zdravljenju.
• pain, including headache, back pain and pain in the pelvis and anal regions, 
• bolečino, vključno z glavobolom, bolečinami v hrbtu in bolečinami v predelu medenice in zadnjika,
● Zirabev can also increase the risk of developing blood clots in your veins (a type of blood vessel). 
● Zdravilo Zirabev prav tako lahko poveča tveganje za pojav krvnih strdkov v venah (vrsta krvnih žil).
Median PFS (months) HR (95% CI) p-value 
mediano PFS (meseci) HR (95 % IZ) p-vrednost
Hazard ratio (95% confidence interval) 
razmerje ogroženosti (95 % interval zaupanja)
In a phase III trial in the adjuvant treatment of patients with colon cancer, a substudy with premenopausal women has shown a higher incidence of new cases of ovarian failure in the bevacizumab group compared to the control group. 
V kliničnem preskušanju 3. faze za adjuvantno zdravljenje bolnikov z rakom debelega črevesa je bila v podštudiji, ki je vključevala ženske pred menopavzo, pojavnost novih primerov okvare jajčnikov večja v skupini z bevacizumabom v primerjavi s kontrolno skupino.
However, sleepiness and fainting have been reported with bevacizumab use. 
Vendar pa so pri uporabi bevacizumaba poročali o zaspanosti in omedlevici.
If you stop treatment with Zirabev 
Če prekinete zdravljenje z zdravilom Zirabev:
The safety and efficacy have not been studied in patients with hepatic impairment (see section 5.2). 
Bolniki z jetrno okvaro Varnosti in učinkovitosti pri bolnikih z jetrno okvaro niso proučevali (glejte poglavje 5.2).
• a brain condition with symptoms including seizures (fits), headache, confusion, and changes in vision (Posterior Reversible Encephalopathy Syndrome or PRES), 
• bolezen možganov s simptomi, ki vključujejo epileptične napade, glavobol, zmedenost in spremembe vida (sindrom posteriorne reverzibilne encefalopatije ali PRES),
Grade 4 proteinuria (nephrotic syndrome) was seen in up to 1.4% of patients treated with bevacizumab. 
Proteinurijo stopnje 4 (nefrotski sindrom) so opazili pri največ 1,4 % bolnikov, ki so se zdravili z bevacizumabom.
When used for patients with breast cancer, it will be administered with a chemotherapy medicinal product called paclitaxel. 
Kadar ga uporabljamo za bolnike z rakom dojk, ga dajemo skupaj s kemoterapevtikom, ki se imenuje paklitaksel.
If this is well-tolerated the second infusion may be given over 60 minutes. 
Če jo boste dobro prenesli, boste lahko drugo infuzijo prejeli v 60 minutah.
Hypersensitivity reactions/infusion reactions (see section 4.8) 
Preobčutljivostne reakcije/reakcije na infuzijo (glejte poglavje 4.8)
Results from the randomised phase III studies, PACCE and CAIRO-2, in patients with mCRC suggest that the use of anti-EGFR monoclonal antibodies panitumumab and cetuximab, respectively, in combination with bevacizumab plus chemotherapy, is associated with decreased PFS and/or OS, and with increased toxicity compared with bevacizumab plus chemotherapy alone. 
Rezultati randomiziranih študij 3. faze, PACCE in CAIRO-2, pri bolnikih z mCRC kažejo, da je uporaba monoklonskih protiteles proti EGFR, panitumumaba in cetuksimaba, v kombinaciji z bevacizumabom in kemoterapijo povezana s skrajšanjem preživetja brez napredovanja bolezni (PFS - progression-free survival) in/ali celokupnega preživetja (OS - overall survival) ter s povečano toksičnostjo v primerjavi samo z bevacizumabom in kemoterapijo.
In the post-marketing setting, cases of foetal abnormalities in women treated with bevacizumab alone or in combination with known embryotoxic chemotherapeutics have been observed (see section 4.8). 
V obdobju trženja so opazili primere nenormalnosti ploda pri ženskah, ki so se zdravile s samim bevacizumabom ali bevacizumabom v kombinaciji z znano embriotoksičnimi kemoterapevtiki (glejte poglavje 4.8).
The other ingredients are sucrose, succinic acid, disodium edetate, polysorbate 80, sodium hydroxide (for pH adjustment), and water for injections. 
Druge sestavine zdravila so saharoza, jantarna kislina, dinatrijev edetat, polisorbat 80, natrijev hidroksid (za uravnavanje pH) in voda za injekcije.
• hole in the gall bladder (symptoms and signs may include abdominal pain, fever, and nausea/vomiting). 
• predrtje žolčnika (simptomi in znaki lahko vključujejo bolečino v trebuhu, vročino in siljenje na bruhanje/bruhanje).
This phase III clinical trial compared rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone (R-CHOP) plus bevacizumab to R-CHOP without bevacizumab. 
V tem kliničnem preskušanju 3. faze so primerjali shemo rituksimab/ciklofosfamid/doksorubicin/vinkristin/prednizon (R-CHOP) z bevacizumabom in shemo R-CHOP brez bevacizumaba.
Sucrose, succinic acid, disodium edetate, polysorbate 80, sodium hydroxide, water for injections. 
Saharoza, jantarna kislina, dinatrijev edetat, polisorbat 80, natrijev hidroksid, voda za injekcije.
Zirabev must be administered under the supervision of a physician experienced in the use of antineoplastic medicinal products. 
Zdravilo Zirabev je treba dajati pod nadzorom zdravnika, ki ima izkušnje z uporabo zdravil za zdravljenje novotvorb.
Arterial thromboembolism 
Arterijska trombembolija
The efficacy results are presented in Table 13 Table 13 Efficacy results for trial BO17705 
Preglednica 13 Rezultati učinkovitosti v preskušanju BO17705
• clogging of a very small blood vessel(s) in the kidney, 
• strdke v zelo majhni krvni žili (ali žilah) v ledvicah,
An overall survival benefit has been demonstrated in trial E4599 with a 15 mg/kg/q3wk dose of bevacizumab. 
Korist pri celokupnem preživetju so dokazali v preskušanju E4599 z odmerkom bevacizumaba 15 mg/kg vsake 3 tedne.
Reactions were reported at various time points during treatment ranging from one week to greater than 1 year from initiation of bevacizumab, with most reactions occurring within the first 6 months of therapy. 
O neželenih učinkih so poročali ob različnih časovnih točkah med zdravljenjem, in sicer v obdobju od 1 tedna do več kot 1 leta od začetka zdravljenja z bevacizumabom.
• Hypersensitivity to Chinese Hamster Ovary (CHO) cell products or other recombinant human or humanised antibodies. 
Preobčutljivost na produkte ovarijskih celic kitajskega hrčka (CHO - Chinese hamster ovary) ali na druga rekombinantna humana ali humanizirana protitelesa.
• muscle and joint pain, muscular weakness, 
• bolečine v mišicah in sklepih, mišično oslabelost,
In rabbits, bevacizumab was shown to inhibit wound healing at doses below the proposed clinical dose. 
Pri kuncih je bevacizumab zaviral celjenje ran pri odmerkih, ki so bili manjši od predlaganega kliničnega odmerka.